The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases
Abstract
Purpose: To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer. Patients and Methods: Clinical outcomes of patients in two large databases were analyzed as a function of steroid receptor status. The first database (PP), contained 3,739 patients who did not receive any systemic adjuvant therapy and 1,688 patients who received adjuvant endocrine therapy but no chemotherapy. The second database (SPORE), contained 10,444 patients who received adjuvant endocrine therapy but no chemotherapy. Biochemical ER and PgR assays were identically performed in two different central laboratories. Results: In univariate and multivariate analyses, the prognostic significance of PgR status among systemically untreated patients is modest. Among endocrine-treated patients, however, multivariate analyses, including lymph-node involvement, tumor size, and age, demonstrate that PgR status is independently associated with disease-free and overall survival. For recurrence, the reduction in relative risk (RR) was 25% for ER-positive/PgR-negative patients and 53% for ER-positive/PgR-positive patients, compared with ER-negative/PgR-negative patients (P < .0001, PP patients). Patients with ER-positive/PgR-negative tumors have a reduction in RR of death of 30% (SPORE patients) and 38% (PP patients), compared with patients with ER-negative/PgR-negative tumors (P < .0001). For ER-positive/PgR-positive tumors, the reduction of the risk of death was greater than 46% in SPORE patients and 58% in PP patients, indicating that ER-positive/PgR-positive patients derive more benefit from endocrine therapy (P < .0001). Conclusion: When accurately measured, PgR status is an independent predictive factor for benefit from adjuvant endocrine therapy. Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Self-citationEllis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis
Horowitz, K. B., McGuire, W. L., Pearson, O. H., & Segaloff, A. (1975) · Science · doi:10.1126/science.168640 · Cited by 569
Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
Fuqua, S. A. W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O’Malley, B. W., & McGuire, W. L. (1991) · PubMed · Cited by 394
Elledge, R. M., Green, S., Pugh, R., Allred, D. C., Clark, G. M., Hill, J., Ravdin, P., Martino, S., & Osborne, C. K. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2<111::aid-ijc2>3.0.co;2-w · Cited by 325
Self-citationBreast Cancer Prognostic Factors: Evaluation Guidelines
McGuire, W. L. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.3.154 · Cited by 295
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens
Dressler, L. G., Seamer, L. C., Owens, M. A., Clark, G. M., & McGuire, W. L. (1988) · Cancer · doi:10.1002/1097-0142(19880201)61:3<420::aid-cncr2820610303>3.0.co;2-0 · Cited by 294
Self-citationTime-dependence of hazard ratios for prognostic factors in primary breast cancer
Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamness, G. C., Osborne, C. K., & Clark, G. M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006133418245 · Cited by 237
Self-citationADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL
Breast Cancer Trials Committee (1987) · The Lancet · doi:10.1016/s0140-6736(87)90762-8 · Cited by 225
Evaluation of estrogen receptor assays in human breast cancer tissue.
Wl, M., De La Garza, M., & Chamness, G. C. (1977) · PubMed · Cited by 202
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
Fernö, M., Stål, O., Baldetrop, B., Hatschek, T., Källström, A.-C., Malmström, P., Nordenskjöld, B. A., & Rydén, S. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006332423620 · Cited by 94
Measurement of progesterone receptor in human breast cancer biopsies.
Powell, B. L., Garola, R. E., Chamness, G. C., & McGuire, W. L. (1979) · PubMed · Cited by 70
Time-Dependent Relevance of Steroid Receptors in Breast Cancer
Coradini, D., Daidone, M. G., Boracchi, P., Biganzoli, E. M., Oriana, S., Bresciani, G., Pellizzaro, C., Tomasic, G., di Fronzo, G., & Marubini, E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2702 · Cited by 55
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Dunnwald, L. K., Rossing, M. A., & Li, C. I. (2007) · Breast Cancer Research · doi:10.1186/bcr1639 · Cited by 785
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Metadata
- Authors
- Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-05-15
- Volume
- 21
- Issue
- 10
- Pages
- 1973-1979
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123179063
- Cited by
- 752
- References
- 18
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.